Insomnia therapeutic - Blake Insomnia Therapeutics

Drug Profile

Insomnia therapeutic - Blake Insomnia Therapeutics

Alternative Names: Zleepax; ZLX-1

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Zleepax
  • Developer Blake Insomnia Therapeutics
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Insomnia

Most Recent Events

  • 09 Feb 2017 Blake Insomnia Therapeutics and Sajo Consulting agree to co-promote and co-develop Zleepax™ for Insomnia
  • 09 Feb 2017 Blake Insomnia Therapeutics announces intention to submit NDA to Health Canada in second quarter of 2017
  • 09 Feb 2017 Blake Insomnia Therapeutics plans a phase II trial for Insomnia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top